Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

Oska_Wellness_Debuts_NextGeneration_Technology-974d14ca348d275a89fdc9ce38feb425-12bto234-1-1.jpg

January 3, 2019 OrthoSpineNews

CARLSBAD, Calif.Jan. 3, 2019 /PRNewswire/ — Oska Wellness, a pioneer of technology-driven wellness solutions dedicated to addressing the chronic pain epidemic in the U.S., will debut its next-generation Oska Pulse device at Pepcom’s Digital Experience! from 7:00 to 10:30 pm on Monday, January 7, 2019 at the Mirage hotel in Las Vegas. Like its predecessor, the new Oska Pulse is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and alleviate pain using Pulsed Electromagnetic Field (PEMF) technology. Key advancements of the device provide added customer convenience and include:

  • Three times longer sessions for 90-minute PEMF pain relief sessions
  • 50 percent longer battery life – 15-hour total run time

A new CDC report found that overdoses corresponding strongly with use of synthetic opioids increased nearly 10 percent year-over-year in 2017 and, as a result, the average American life expectancy has been reduced by nearly four months for the first time since WWII. Pepcom’s Digital Experience! attendees are invited to visit Oska’s table at the show to learn more and test out the innovative new Oska Pulse device. Greg Houlgate, co-founder of Oska Wellness, will be available to discuss and demonstrate Oska Pulse, PEMF technology and how his personal experience with pain led him to recognize the need for an easy to use, affordable, drug-free pain relief alternative in the U.S.

“Chronic pain disrupts the lives of over 100 million Americans daily and is the leading cause of long-term disability in the U.S., affecting more people than diabetes, heart disease and cancer combined,” said Houlgate. “It’s very clear that the United States is fighting a battle with pain. Oska Pulse addresses this issue at the source and brings affordable, drug-free pain relief to those who need it most.”

Oska Pulse provides clinically-proven pain relief in the convenience of a wearable, portable and shareable PEMF device that seamlessly fits into any lifestyle. While PEMF technology is commonly used in doctors’ offices worldwide and is demonstrated in thousands of clinical studies to work at the source of pain and provide relief, Oska Pulse is the first device to make it available at an accessible price for home use. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication.

The new Oska Pulse device will be available for purchase in January 2019 for $399 online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

About Oska Wellness

Co-founded in 2015 by Greg Houlgate, Oska Wellness is a pioneer of technology-driven wellness solutions that help people live more active lives with less pain. The brand’s cornerstone product, Oska Pulse, is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and relieve pain. Oska Pulse utilizes Pulsed Electromagnetic Field (PEMF) technology, which is commonly used in doctors’ offices and clinically proven to work at the source of pain by accelerating the body’s ability to repair injured cells and increasing blood flow. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication. Oska Pulse can be purchased online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

Contact: Megan Busch 
Rachel Kay Public Relations 
858-922-5045 
207077@email4pr.com

SOURCE Oska Wellness

Related Links

https://www.oskawellness.com


Oska_Wellness_Debuts_NextGeneration_Technology-974d14ca348d275a89fdc9ce38feb425-12bto234-1.jpg

January 3, 2019 OrthoSpineNews

CARLSBAD, Calif.Jan. 3, 2019 /PRNewswire/ — Oska Wellness, a pioneer of technology-driven wellness solutions dedicated to addressing the chronic pain epidemic in the U.S., will debut its next-generation Oska Pulse device at Pepcom’s Digital Experience! from 7:00 to 10:30 pm on Monday, January 7, 2019 at the Mirage hotel in Las Vegas. Like its predecessor, the new Oska Pulse is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and alleviate pain using Pulsed Electromagnetic Field (PEMF) technology. Key advancements of the device provide added customer convenience and include:

  • Three times longer sessions for 90-minute PEMF pain relief sessions
  • 50 percent longer battery life – 15-hour total run time

A new CDC report found that overdoses corresponding strongly with use of synthetic opioids increased nearly 10 percent year-over-year in 2017 and, as a result, the average American life expectancy has been reduced by nearly four months for the first time since WWII. Pepcom’s Digital Experience! attendees are invited to visit Oska’s table at the show to learn more and test out the innovative new Oska Pulse device. Greg Houlgate, co-founder of Oska Wellness, will be available to discuss and demonstrate Oska Pulse, PEMF technology and how his personal experience with pain led him to recognize the need for an easy to use, affordable, drug-free pain relief alternative in the U.S.

“Chronic pain disrupts the lives of over 100 million Americans daily and is the leading cause of long-term disability in the U.S., affecting more people than diabetes, heart disease and cancer combined,” said Houlgate. “It’s very clear that the United States is fighting a battle with pain. Oska Pulse addresses this issue at the source and brings affordable, drug-free pain relief to those who need it most.”

Oska Pulse provides clinically-proven pain relief in the convenience of a wearable, portable and shareable PEMF device that seamlessly fits into any lifestyle. While PEMF technology is commonly used in doctors’ offices worldwide and is demonstrated in thousands of clinical studies to work at the source of pain and provide relief, Oska Pulse is the first device to make it available at an accessible price for home use. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication.

The new Oska Pulse device will be available for purchase in January 2019 for $399 online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

About Oska Wellness

Co-founded in 2015 by Greg Houlgate, Oska Wellness is a pioneer of technology-driven wellness solutions that help people live more active lives with less pain. The brand’s cornerstone product, Oska Pulse, is a revolutionary drug-free pain relief device that is clinically proven to reduce inflammation, increase circulation, improve mobility and relieve pain. Oska Pulse utilizes Pulsed Electromagnetic Field (PEMF) technology, which is commonly used in doctors’ offices and clinically proven to work at the source of pain by accelerating the body’s ability to repair injured cells and increasing blood flow. Unlike many other pain intervention therapies, Oska Pulse has no known side effects, is non-invasive, lightweight, portable, shareable, and provides safe, effective and affordable access to pain relief – all without medication. Oska Pulse can be purchased online at www.oskawellness.comFSAstore.comHSAstore.com and Amazon. To learn more about Oska, visit www.oskawellness.com.

Contact: Megan Busch 
Rachel Kay Public Relations 
858-922-5045 
207077@email4pr.com

SOURCE Oska Wellness

Related Links

https://www.oskawellness.com


cartiheal-12bto2-1.png

December 19, 2018 OrthoSpineNews

KFAR SABA, Israel and COLUMBUS, OhioDec. 19, 2018 /PRNewswire/ — CartiHeal, developer of Agili-C, a proprietary implant for the treatment of joint surface lesions, announced today the successful enrollment of the first patient in the Agili-C Investigational Device Exemption (IDE) pivotal study at The Ohio State University Wexner Medical Center.

The surgery was performed by site Investigators Dr. Christopher Kaeding and Dr. David Flanigan at The Ohio State University Wexner Medical Center in Columbus, Ohio. The Ohio State University Wexner Medical Center is one of 30 U.S. and O.U.S sites in the new Food and Drug Administration (FDA) IDE trial aiming to show the superiority of the Agili-C implant over the current standard of care in the treatment of cartilage defects in arthritic and non-arthritic knees.

The first patient enrolled at The Ohio State University Wexner Medical Center had mild osteoarthritis and two cartilage lesions on both of the femoral condyles. “We are very happy that our first patient in the study was randomized to the Agili-C arm. The patient was treated with two implants, one each condyle,” said Dr. Kaeding. “Dr. Flanigan and I look forward to expanding upon our initial successful clinical procedure.”

“We are excited with the first enrollment at The Ohio State University Wexner Medical Center,” said CartiHeal’s Founder and CEO, Nir Altschuler. “The site is of great importance due to its strong professional reputation and strategic location, and we look forward to a fruitful collaboration with Dr. Kaeding and Dr. Flanigan.” The pivotal study aims to show the superiority of the Agili-C implant over the current standard of care in the treatment of cartilage defects in arthritic and non-arthritic knees.

About the Agili-C™ Implant

Agili-C™ is a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects in traumatic and osteoarthritic joints. The implant is a porous, biocompatible, and resorbable bi-phasic scaffold, consisting of interconnected natural inorganic calcium carbonate (aragonite).

The Agili-C™ implant is CE marked for use in cartilage and osteochondral defects. Agili-C™ has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.

Agili-C™ IDE Clinical Study

The clinical study is a prospective, multi-center, open-label, randomized, and controlled trial aims to show the superiority of the Agili-C™ implant over the current surgical standard of care, micro-fracture or debridement, for the treatment of variety of cartilage lesions of the knee.

For more information please refer to https://www.cartiheal.com/

About CartiHeal

With offices in Closter, New Jersey, and Kfar Saba, Israel, CartiHeal, a privately-held medical device company develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.

In the United States, the Agili-C implant is not available for sale – it is an investigational device limited for use in the IDE study.

Contact
Wexner Medical Center, The Ohio State University
Columbus, Ohio   
Courtney.Wright@osumc.edu

CartiHeal
info@cartiheal.com   
www.cartiheal.com

SOURCE CartiHeal

Related Links

https://www.cartiheal.com


wishbone-1234-12-1-121212-1.jpg

December 14, 2018 OrthoSpineNews

WARSAW, Ind., Dec. 14, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc. has been granted a global, non-exclusive license for the sale of a patented guided growth plating system in children with deformed limbs.  These 3 patents were created and designed for the gradual correction of pediatric deformities in both the upper and lower extremities.

WishBone Medical is designing and developing its own guided growth plate and instrumentation systems in sterile packed, single use, disposable kits.  This product will come in both the 2-hole and 4-hole plates systems in multiple sizes as well as options in stainless steel and titanium.  The anticipated launch will be in first quarter 2019, following FDA Clearance.

Nick Deeter, Chairman of the Board WishBone Medical, said, “We are excited to enter into this license agreement of patented technologies to develop, produce and sell our guided growth systems.  These systems will provide global access in sterile packed, single use disposable kits for children who are suffering with these pediatric deformities around the world.”  Mr. Deeter added, “With this sterile packed system, we can go into hospitals and surgery centers that have not had access to the traditional reusable systems.”

Dr. Robert von Seggern, Executive Vice President at WishBone Medical, commented, “As a dedicated pediatric orthopedic company, WishBone Medical needed this product to round out its large portfolio of orthopedic implants designed specifically for children with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.  WishBone Medical currently has 42 pediatric orthopedic product systems with operations in Warsaw, IN, Istanbul, Turkey, and Singapore.

For further information, visit www.WishBoneMedical.com or call Mary Wetzel, Chief Operating Officer, at 574-306-4006.


nordic-box-djo-12bto-1.jpg

December 12, 2018 OrthoSpineNews

December 12, 2018

DALLAS–(BUSINESS WIRE)–DJO (“DJO” or the “Company”), a leading global provider of medical technologies designed to get and keep people moving, today announced its plans to relocate its global headquarters from San Diego, California to Dallas, Texas by early 2019. DJO’s Bracing and Supports business unit, which develops and markets DonJoy®, the market-leading line of bracing solutions, and DJO’s Consumer business unit will remain in San Diego, California in a new and improved contemporary space.

“We made the strategic decision to move our headquarters to Dallas to expand our presence into a market with a strong and larger pool of talent, gain greater and more efficient customer access and take advantage of what we believe is a better corporate environment for our company as we grow,” said Brady Shirley, DJO’s President and Chief Executive Officer. “At the same time, we felt it was important to continue the 40-year legacy of DonJoy in Southern California by continuing to build our Bracing business in Carlsbad.”

Over the next three months, DJO will transition many of its corporate functions to Dallas, which will serve as the global headquarters for the Company featuring a state-of-the-art customer experience center and a comfortably modern environment that supports employee well-being while encouraging collaboration. In addition to the relocation of many current employees to the new headquarters, DJO is creating hundreds of new job opportunities in the Dallas area, including many at its new distribution center in Fort Worth which opened a few months ago and already employs over 200.

By bringing teams, processes and systems together into one location in close proximity to its new distribution hub in Fort Worth, DJO continues to demonstrate its commitment to delivering value to its customers, employees and shareholders.

“This move is a key component of a multi-phase facility optimization strategy that DJO embarked on earlier in the year to enhance the look and feel of many of our offices, bring teams together and remove unneeded workspace in our U.S. locations,” said Jeanine Kestler, Executive Vice President and Chief Human Resources Officer for DJO. “We are excited to become one of the leading medical device companies headquartered in Dallas and an active member of the community!”

About DJO

DJO is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements relate to, among other things, the Company’s expectations for growth of the Company, the acceleration of innovation and the delivery of value to its customers, employees and shareholders. These forward-looking statements are based on the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause our results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to the successful execution of the Company’s business transformation and facility consolidation plans. Other important factors that could cause results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 16, 2018.

Contacts

DJO Media Contact:
Katie Sweet
Communications Director
Katie.sweet@djoglobal.com

DJO Investor Contact:
David Smith
SVP, Treasurer and Investor Relations
760.734.3075
IR@djoglobal.com


PitStop_2image-12bto2.jpg

December 11, 2018 OrthoSpineNews

December 11, 2018

MEMPHIS, Tenn.–(BUSINESS WIRE)–In2Bones Global, Inc. today announced the global launch of the unique, “see-through” PitStop®implant.

Manufactured from a high-performance polymer called polyether ether ketone (PEEK), the PitStop® Implant is used to help facilitate the surgical correction of progressive flat foot deformity in both pediatric and adult populations.

Flexible flatfoot is one of the most common deformities of the foot, often starting during adolescence and continuing into adulthood. The PitStop® Implant helps to restore the stability of a patient’s arch during the gait or walking process.

Several traditional metallic brands of subtalar implants are currently available today which can be limiting because of the excessive stiffness of the material compared to the adjacent bones, causing pain and biomechanical adaptation in some cases. PEEK has the benefit of being less stiff (softer) than metal and more similar to the elasticity of bone. The PEEK material in the PitStop® Implant may lead to increased and long-term patient tolerance.

Additionally, PEEK is radiolucent, meaning that it won’t show up on X-ray, something that traditional metal implants cannot do because metal absorbs X-rays and blocks the image underneath.

The Unique “see-through” PitStop® Implant demonstrates In2Bones’ commitment to expanding the extremities market by launching innovative technological advancements that improve surgical outcomes and patient care.

To support the commercial launch of the PitStop® Implant, In2Bones recently published the micro website, http://www.PitStop-Implant.com providing physicians and healthcare professionals with easy to access educational content. The materials on the site will include surgical animations and videos, surgical technique guides, case studies, patient support materials, and more.

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones

Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.in2bones.com.

Contacts

Jon Simon | Sr. Vice President of Marketing
In2Bones USA
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com


CoLink_Afx-12bto.jpg

December 4, 2018 OrthoSpineNews

December 04, 2018

MEMPHIS, Tenn.–(BUSINESS WIRE)–In2Bones Global, Inc. today announced the U.S. commercial market release of the CoLink Afx® Ankle Fracture System. The system is a collection of five plate families that address traumatic fractures and osteotomies (removal of bone) of the ankle.

Anatomy specific plate options consist of Lateral Fibula, Posterior-Lateral Fibula, One-Third Tubular, Medial Tibia, and Posterior Tibia. Associated 2.7 and 3.5mm cortical screws are offered with innovative CoLink® VAL- Variable Angle Locking Technology.

The low profile anatomically, designed titanium plates are type II anodized. They provide a stronger smoother surface compared to standard color anodization used in most plates on the market. The ultra-thin plates, along with minimal prominence at the plate and screw head interface, provide additional protection against patients experiencing soft tissue irritation, which can occur with conventional trauma hardware.

“This comprehensive set allows me to fix any pattern of ankle fracture,” says Travis Hanson, MD of Houston Methodist Orthopedics and Sports Medicine.

“It has every type of plate and screw combination that I need,” he says. “The contoured design of the new CoLink® Afx System provides increased confidence that my patients will receive a plate that fits their specific anatomy. These are the most low profile plates that I have used around the ankle.”

“We’re very excited about the commercial market release of the CoLink® Afx System,” says Jon Simon, Sr. Vice President of Marketing at In2Bones. “Expanding our portfolio into the high-volume ankle fracture market with a truly best-in-class product provides tremendous growth opportunities for us heading into 2019.”

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones

Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.in2bones.com.

Contacts

Jon Simon | Sr. Vice President of Marketing
In2Bones USA
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com


WB_Logo-12bto-1-4.png

November 28, 2018 OrthoSpineNews

WARSAW, Ind., Nov. 28, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc. announces the acquisition of Response Ortho. Response Ortho has a complete pediatric line of external and internal fixation and deformity correction products.

Response Ortho has been in business for fourteen years and has built a modern, high-tech manufacturing facility with access to an experienced engineering and technical labor force. Because of this, product development and launch activities have been dramatically accelerated for WishBone Medical with the Response Ortho offering of over thirty developed pediatric orthopedic systems, with multiple patents, including the award winning “Smart Correction” Hexapod Fixator and “Click2Correct” surgical preoperative planning software.  Eighteen of the current product systems can be sold in the US now and we are working on FDA clearance for the remaining products. Our commitment is to provide global access to anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits for children.

Nick Deeter, Chairman of the Board and CEO at WishBone Medical, said, “With the acquisition of Response Ortho, we are thrilled about our pediatric orthopedic product offerings. The combination of Response Ortho’s thirty product systems and WishBone’s eight product systems will give WishBone Medical the broadest product portfolio in pediatric orthopedics worldwide.”  Mr. Deeter added, “These pediatric orthopedic products can be delivered in sterile packed, procedural kits anywhere in the world, next day, to the surgeons that care for children.”

Sehmuz Isin, CEO of Response Ortho said, “We are excited that Response Ortho is now part of WishBone Medical.  Our primary focus has been outside the US, and we will now be able to offer these innovative orthopedic product systems everywhere.  Having more than 50 years of combined experience, Nick and I understand the unmet needs and will provide global solutions to children with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.

About Response Ortho

Response Ortho is a vertically integrated, ISO 13485 certified, CE Mark lean company that is focused on the orthopedic industry with modern equipment and scalable technology. Response Ortho is located in Istanbul, Turkey.

For further information, visit www.WishBoneMedical.com or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.


CoLink-View-news01-12bto-1.png

November 28, 2018 OrthoSpineNews

Memphis, Tenn., (November 27, 2018) – In2Bones Global, Inc. today announces the commercial launch of the CoLink® View Plating System.

CoLink® View Bone Plates, marketed under the CoLink® View brand name, incorporate a unique combination of titanium metal and a high-performance polymer called polyether ether ketone (PEEK).

The CoLink® View Plates offer transverse joint compression through an X-ray transparent PEEK hub. This allows the surgeon to watch the patient’s bone fusion site during the post-surgical healing process.

Traditional metal plates cannot do this because metal absorbs X-rays and blocks the image underneath. The “see-through” hub is unique to this new In2Bones plating system, and one of many device innovations designed by the company.

In addition to X-ray transparency, PEEK has a benefit of being less stiff than metal and more similar to the elasticity of bone. Bones need mechanical stress (elasticity) during the healing process. Stiffer, all metal implants may eliminate the positive elasticity and slow healing.

The CoLink® View is the sixth In2Bones PEEK-related implant system to reach commercialization. It demonstrates In2Bones’ commitment to expanding the extremities market by launching innovative technological advancements to improve surgical outcomes and patient care.

For more information about In2Bones Global, Inc. extremity products, please visit www.In2Bones.com.

About In2Bones
Headquartered in Memphis, Tennessee, In2Bones is a global designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. For more information, visit www.i2b-usa.com.

Safe-Harbor Statement:
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current view of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” and other similar terms. The company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting the business, including increased competition, technical obsolescence, regulatory issues, general economic conditions and other risks.

Media Contacts:
Jon Simon | Sr. Vice President of Marketing
In2Bones USA
6000 Poplar Ave, Suite 115 Memphis, TN 38119
M: 512.739.5793 • O: 901.260.7931 • F: 844-712-6637
Email: jsimon@i2b-usa.com
https://www.linkedin.com/company/22344175/

Bob Reed
Element-R Partners
630.579.1770
bob@rurelevant.com

 


OP.logo_.InnovationTag.4C.TRANSPARENT.registered-12-12bto.png

November 27, 2018 OrthoSpineNews

WARSAW, Ind., Nov. 27, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the U.S. launch of its new PediLoc® Femur Plate System. Building on the success of the existing PediLoc franchise, this upgraded offering boasts a lower profile screw to minimize soft tissue irritation, new locking drill guides, which simplify screw hole drilling and screw placement, and new 4.5mm straight locking compression plate options.

The breadth of this product offering allows surgeons to appropriately address multiple indications in patients with varying skeletal maturity levels by utilizing a plate that accurately fits the femur. Further, the enhanced system is configured for increased hospital and operating room synergy by utilizing OP’s existing core systems.

Joe Hauser, Vice President of Trauma & Deformity Correction, commented, “We are proud of our commitment to delivering innovative products to pediatric orthopedic surgeons. Our commitment to improve our legacy systems while also introducing new surgical systems demonstrates our dedication to providing superior surgical solutions for children. The PediLoc franchise is an important aspect of our business, and this enhanced system will provide our customers with new and improved implant options.”

About PediLoc Femur
The PediLoc Femur Locking Plate System is indicated for the treatment of pediatric femur fractures and osteotomies. The anatomic design of the stainless steel plates eliminates the need for intraoperative bending and contouring, while also providing superior fixation with either locking or non-locking screws.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 25 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 38 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com